Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A solitary adenocarcinoma arising from the lung measuring 3 cm or less. It is characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. It is usually a non-mucinous adenocarcinoma, but rarely may be mucinous.
Biomarker and diagnostic research for minimally invasive lung adenocarcinoma has been reported in the published literature.
4 clinical trials registered. Interventions under study include procedural interventions, biologic therapy, drug therapy, and other interventions. Pipeline includes 3 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.
12 publications have been identified in PubMed for minimally invasive lung adenocarcinoma. Research spans Basic Science / Preclinical (42%), Case Report / Case Series (25%), and Diagnostic / Biomarker (8%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 5 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 1:02 AM UTC
42%
Patient case studies | 3 | 25% |
Testing and diagnosis research | 1 | 8% |
Clinical study results | 1 | 8% |
Disease patterns and progression | 1 | 8% |
New treatment approaches | 1 | 8% |
Gambino G (2026). [PMID: 42196305](https://pubmed.ncbi.nlm.nih.gov/42196305/). *Int J Mol Sci*. [Basic Science / Preclinical]
Wang Z (2026). [PMID: 41216859](https://pubmed.ncbi.nlm.nih.gov/41216859/). *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*. [Basic Science / Preclinical]
Xing X (2026). [PMID: 41180847](https://pubmed.ncbi.nlm.nih.gov/41180847/). *Oncology letters*. [Case Report / Case Series]
Isoyama S (2026). [PMID: 41912380](https://pubmed.ncbi.nlm.nih.gov/41912380/). *Thorac Cancer*. [Basic Science / Preclinical]
Wang CH (2025). [PMID: 40972814](https://pubmed.ncbi.nlm.nih.gov/40972814/). *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. [Case Report / Case Series]
Liu B (2025). [PMID: 40758603](https://pubmed.ncbi.nlm.nih.gov/40758603/). *Molecular pharmaceutics*. [Gene Therapy / Novel Therapeutics]
Chae YK (2025). [PMID: 39487975](https://pubmed.ncbi.nlm.nih.gov/39487975/). *The oncologist*. [Case Report / Case Series]
Tseng TC (2024). [PMID: 39795569](https://pubmed.ncbi.nlm.nih.gov/39795569/). *Diagnostics (Basel, Switzerland)*. [Diagnostic / Biomarker]
Liao Y (2024). [PMID: 38778366](https://pubmed.ncbi.nlm.nih.gov/38778366/). *World journal of surgical oncology*. [Epidemiology / Natural History]
Sheema AN (2024). [PMID: 39269499](https://pubmed.ncbi.nlm.nih.gov/39269499/). *Archives of toxicology*. [Basic Science / Preclinical]